| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sebastiano Buti, Melissa Bersanelli, Francesco Massari, Ugo De Giorgi, Orazio Caffo, Gaetano Aurilio, Umberto Basso, Giacomo Carteni, Claudia Caserta, Luca Galli, Francesco Boccardo, Giuseppe Procopio, Gaetano Facchini, Giuseppe Fornarini, Alfredo Berruti, Elena Fea, Emanuele Naglieri, Fausto Petrelli, Roberto Iacovelli, Camillo Porta and Alessandra Mosca |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Melissa Bersanelli, MD, Adjunct Professor, Postdoctoral Fellow, Staff Physician, Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma 43126, Italy. bersamel@libero.it |
| Key Words |
Pazopanib; Non-clear cell; Kidney cancer; Renal-cell carcinoma; Variant histology; Tyrosine kinase inhibitors |
| Core Tip |
Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) have dismal results with standard systemic therapies and poor prognosis. Few therapeutic molecules have been tested specifically in nccRCC patients. We retrospectively collected 48 advanced nccRCC patients treated with pazopanib in first-line setting, offering reassuring findings about quite good response rate (27%), progression-free survival around 12 mo and overall survival around 28 mo. We suggested, in light of these results, that pazopanib can be a good treatment choice in this subgroup of patients, pending the results of ongoing clinical trials with new therapeutic combinations. |
| Publish Date |
2021-11-19 09:32 |
| Citation |
Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol 2021; 12(11): 1037-1046 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i11/1037.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i11.1037 |
